
An abstract from the American Heart Association's Scientific Sessions 2026 reveals the continuous expansion of the GLP-1 medication class.
You'll be seeing a lot of the term downstream entity. That's the handle CMS proposes to use to signify pharmacies or pharmacists who contract with PBMs, dubbed first-tier entities, that, in turn, contract with Part D plan sponsors.






